Everolimus in relapsed Hodgkin's lymphoma: something exciting or a case of caveat mTOR?
Rule
Simon
S
Peninsula Medical School, Derriford Hospital, Plymouth, PL6 8DH, United Kingdom. simon.rule@phnt.swest.nhs.uk
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D000068338:Everolimus; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D000068338:Everolimus; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus